Primaquine: Difference between revisions
(Text replacement - "* " to "*") |
(Restore original dosing content alongside dynamic SMW tables) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Antimalarial]], anti-[[PCP]] | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: oral | *Routes of Administration: oral | ||
| Line 9: | Line 9: | ||
*[[Malaria]] treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent | *[[Malaria]] treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent | ||
*[[Malaria]] prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | *[[Malaria]] prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Primaquine]] [[Has Population::Adult]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*[[Malaria]] treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent | *[[Malaria]] treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent | ||
*[[Malaria]] prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | *[[Malaria]] prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure | ||
===Indications by Disease=== | |||
{{#ask: [[Has DrugName::Primaquine]] [[Has Population::Pediatric]] | |||
|?Treats disease=Disease | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|format=table | |||
|limit=50 | |||
|mainlabel=- | |||
|headers=show | |||
|sort=Treats disease | |||
}} | |||
==Special Populations== | ==Special Populations== | ||
| Line 48: | Line 74: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:ID]] | |||
Latest revision as of 02:39, 20 March 2026
Administration
- Type: Antimalarial, anti-PCP
- Dosage Forms:
- Routes of Administration: oral
- Common Trade Names:
Adult Dosing
- PCP pneumonia, HIV+ : 15-30mg PO daily with clindamycin
- Malaria treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent
- Malaria prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Pneumocystis jirovecii pneumonia | 30mg PO q24hrs | Mild disease with Clindamycin |
| Pneumocystis jirovecii pneumonia | 30mg PO once daily | Severe disease with Clindamycin |
Pediatric Dosing
- Malaria treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent
- Malaria prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure
Indications by Disease
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing:
Contraindications
- Allergy to class/drug
- Concomitant use with other potentially hemolytic or myeloid suppressing drugs
- Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)
Adverse Reactions
Serious
- Hemolytic anemia, leukopenia
- Methemoglobinemia
Common
- Nausea, abdominal pain
Pharmacology
- Half-life: 4-7 hours
- Metabolism:
- Excretion:
Mechanism of Action
- Eliminates tissue infection, thus preventing erythrocytic forms of parasite